Retatrutide - Top-Line Results from TRIUMPH 4 — The Obesity Doctor Podcast

Listen in the Podli app 🎧

Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.

In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.

Highlights:

Up to 28.7% weight loss (~71 lbs) over 68 weeks
75% reduction in knee pain and major improvements in physical function
Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure

We also cover

Common side effects and safety signals
Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications
A reality check on Canadian availability (likely 3+ years away)
A strong warning about illegal online sales and the risks of buying unregulated products

A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.